Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
Tempo Therapeutics’ $12 Million Series A Financing Round
Arena BioWorks’ Launch
Wilson Sonsini Goodrich & Rosati advised Arena BioWorks on patent and transactional matters. Arena BioWorks announced its launch as a biomedical research institute with a mission...
JIXING’s Collaborations with TMS
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
C4 Therapeutics’ License and Research Collaboration with Merck
Wilson Sonsini Goodrich & Rosati advised C4 Therapeutics on the transaction. C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced that it has entered into an exclusive license...
JURA Bio’s $16.1 Million Financing and Replay Collaboration
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
Delve Bio’s $35 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Delve Bio in the transaction. Delve Bio announced it has debuted with $35 million in Series A financing led by Perceptive...
Zymeworks’ Exclusive Licensing Agreement with Jazz Pharmaceuticals
Wilson Sonsini advised Zymeworks on the deal. Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop...
Galapagos’ Acquisition of CellPoint
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
Cellino’s $80 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
Chroma Medicine’s $125 Million Financing
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
Recursion’s Collaboration with Roche and Genentech
Wilson Sonsini Goodrich & Rosati advised Recursion on the deal. Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development,...
AbSci’s Acquisition of Totient
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...